52-LB: One-Year Results from VLCD vs. Time-Restricted Eating

Abstract

There continues to be debate about eating patterns, glucose, and weight control in people with type 2 diabetes. Recently, very low carbohydrate diets (VLCD) have had success in clinical trials. Intermittent fasting or time-restricted eating (TRE) has gained community popularity. In this pilot study, we report follow-up data from a study that randomized participants to VLCD and TRE. A total of 32 participants completed the initial protocol (16 VLCD, 16 TRE). Participants were invited to participate in a 1-year observational follow-up period with phone assessment every 3 months to assess the long-term impacts of the protocol on HbA1c, lipid profile, anthropometrics, and medication regime. Twelve participants (8 VLCD, 5TRE) agreed to follow up. The mean HbA1c in the VLCD was 8.04% at baseline (N=5), mean HbA1c of 8.6% at 6 months (N=3), 8.2% at 9 months (N=1), and 8.63% at 12 months (N=3). For the VLCD group, mean weight was 262lbs at baseline (N=5), 259lbs at 3 months (N=1), 232.5lbs at 6 months (N=2), and 229.4lbs at 12 months (N=5). For the TRE group, the mean A1c was 8.65% at baseline (N=8), 8.5% at 3 months (N=2), 7.8% at 6 months (N=3), 9.4% at 9 months (N=4), and 8.25% at 12 months (N=2). The TRE mean weight was 231.25lbs at baseline (N=8), 237.4lbs at 6 months (N=2), 199.1lbs at 9 months (N=5), and 230.1lbs at 12 months (N=2). While the sample size was small, this study followed participants for 1-year after a 1-month nutritional intervention and illustrated that these dietary plans resulted in different success parameters. Disclosure A. Nijjar: None. R. Kiwan: None. T. L. Calinawan: None. J. H. Shubrook: Advisory Panel; AstraZeneca, Eli Lilly and Company, Nevro Corp., Consultant; Abbott Diabetes, Bayer Inc., Novo Nordisk.